Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-κB activity

C Cherbonnier1, O Déas2,5, G Carvalho1,5, G Vassai3, A Dürrbach1, A Haeffner1, B Charpentier1, J Bénard4 and F Hirsch*,1

1INSEERM U542, Paris XI University, Villejuif Cedex, France; 2Targa Therapies, Villejuif Cedex, France; 3Institut Gustave Roussy and UMR8532, Villejuif Cedex, France; 4Genetic Markers Unit, Institut Gustave Roussy, Villejuif, France

In addition to its primary role as growth factor, human growth hormone (hGH) can also participate in cell survival, as already documented by its protective effect on human monocytes or human promyelocytic leukaemia U937 cells exposed to a Fas-mediated cell death signal. However, despite similarities in the molecular events following Fas and TNF-α receptor engagement, we report that U937 cells, genetically engineered to constitutively produce hGH, were made more sensitive to TNF-α-induced apoptosis than parental cells. This was due to overproduction of the antioxidant glutathione, which decreased the nuclear factor (NF)-κB activity known to control the expression of survival genes. These findings were confirmed in vivo, in nude mice bearing U937 tumours co-injected with recombinant hGH and the NF-κB-inhibiting anticancer drug daunorubicin, to avoid the in vivo toxicity of TNF-α. This study therefore highlights one of the various properties of hGH that may have potential clinical implications.

British Journal of Cancer (2003) 89, 1108–1115. doi:10.1038/sj.bjc.6601223 www.bjcancer.com
© 2003 Cancer Research UK

Keywords: growth hormone; apoptosis; glutathione; NF-κB

It has now been clearly established that the human growth hormone (hGH), secreted by the pituitary gland, exerts various important properties in addition to its fundamental role as a growth factor (reviewed in van Buul-Offers and Kooijman, 1998). This finding led to the use of hGH as adjuvant therapy in various diseases, such as AIDS (Lee, 1996), heart failure (Sacca and Fazio, 1996) or Crohn’s disease (Slonim, 1996) or Crohn’s disease (Slonim, 1996) or Crohn’s disease (Slonim, 1996) or Crohn’s disease (Slonim, 1996) or Crohn’s disease (Slonim, 1996). Yet, despite similarities in the molecular events following Fas and TNF-α receptor engagement, we report that U937 cells, genetically engineered to constitutively produce hGH, were made more sensitive to TNF-α-induced apoptosis than parental cells. This was due to overproduction of the antioxidant glutathione, which decreased the nuclear factor (NF)-κB activity known to control the expression of survival genes. These findings were confirmed in vivo, in nude mice bearing U937 tumours co-injected with recombinant hGH and the NF-κB-inhibiting anticancer drug daunorubicin, to avoid the in vivo toxicity of TNF-α. This study therefore highlights one of the various properties of hGH that may have potential clinical implications.

British Journal of Cancer (2003) 89, 1108–1115. doi:10.1038/sj.bjc.6601223 www.bjcancer.com
© 2003 Cancer Research UK

Keywords: growth hormone; apoptosis; glutathione; NF-κB

In a recent study, we also reported that hGH may modulate the response of cells to apoptotic signals, demonstrating its beneficial effect on the survival of human monocytes and promyelocytic leukaemia U937 cells exposed to a proapoptotic signal mediated via Fas engagement (Haeffner et al, 1999). In parallel, we exposed our U937 cell lines to TNF-α, expecting similar protection, as Fas is a member of the tumour necrosis factor (TNF) receptor superfamily (Itoha et al, 1991; Oehm et al, 1992), and shares common signalling pathways with the type 1 TNF receptor (Hsueh et al, 1996), including in U937 cells (Schütze et al, 1992; Gifone et al, 1993). In contrast, as reported herein, we observed that hGH sensitised U937 cells to the apoptotic signal induced by TNF-α. The effect of hGH is mediated via a glutathione-dependent decrease in NF-κB translocation normally observed in response to TNF-α. We also
confirmed these findings in vivo, as injections of exogenous recombinant hGH in U937 tumour-engrafted nude mice led to increased tumour cell death together with decreased translocation of NF-κB in cell nuclei, in response to subtoxic doses of daunorubicin, an anthracycline agent activating NF-κB in our cells (Cherbonnier et al, 2002).

MATERIALS AND METHODS

Cells and culture conditions

Two different human myeloid leukaemia U937 cell lines producing 10–50 ng ml⁻¹ of hGH after stable gene transfer (U937-hGH-A and U937-hGH-H5) and the control line (U937-Neo), already described (Haefner et al, 1999), were maintained in regular FCS-enriched RPMI 1640 medium (Bio-Whittaker Europe, Verviers, Belgium) containing 0.5 mg ml⁻¹ of G418 (Life Technology, Paisley, Scotland).

Assessment of apoptosis

U937 cells (5 × 10⁵) (the two hGH-transfected and the control lines) in 0.5 ml of culture medium were cultured for 48 h in the presence or absence of TNF-α (Innotest, Besançon, France) with or without 400 ng ml⁻¹ of cycloheximide (CHX, Sigma, St Louis, MO, USA), as previously reported (Cossarizza et al, 1995). Dead cells were detected either by trypan blue exclusion for experiments run in the presence of recombinant hGH (rhGH, Saizen®, kindly provided by Serono France) at doses already experimented (Haefner et al, 1999) or by flow cytometry analysis of cell lines after a 15 min staining with propidium iodide (PI) (5 μg ml⁻¹ pi, Sigma, St-Louis, MO, USA), using a FacsScan (Recon Dickinson, Mountain View, CA, USA). Hypoploid cell assessment was measured on ethanol-permeabilised U937 cells exposed or not to 10 ng ml⁻¹ of TNF-α cultured overnight with or without 400 ng ml⁻¹ of cycloheximide (CHX), by staining with PI, as previously described (Mollerreau et al, 1996). In separate experiments, we added glutathione ethyl ester (GSH-OEt) (Sigma) to the culture of control U937 cells in the presence or absence of TNF-α.

NF-κB measurement

Cell lines were cultured for 90 min in the presence of 10 ng ml⁻¹ TNF-α, and nuclear extracts were analysed by electrophoretic mobility-shift assay (EMSA). Specificity was assessed by incubating nuclear extracts obtained from TNF-α-stimulated cells with nonradiolabelled NF-κB probe (5′-ACAAAGGGACATTTGCCGCTGGG-GACCTTCCAG-3′) or mutated NF-B (5′-ACAACTCATTTCGC-GCTGCTCACTTTCCAG-3′) oligonucleotide probe, as previously reported (Thiéblemont et al, 1995). For supershift assays, anti-P50 Abs (kindly provided by A Israël, Institut Pasteur) after stripping, and then with anti-rabbit peroxidase-labelled second Abs (anti-rabbit peroxidase-labelled goat anti-rabbit Abs, and nuclei were stained with nuclei were stained with

Glutathione measurement

The total glutathione level was measured by the glutathione reductase recycling method, as previously described (Déas et al, 1997). Glutathione is expressed in nmol·mg⁻¹ of total protein measured in cell extracts by the Bradford method.

In vivo experiments

U937 cells (10⁵) were first injected subcutaneously into irradiated 6- to 8-week-old male nu/nu Swiss mice in order to obtain solid tumours. Another group of mice was then engrafted with fragments from these tumours (4 mm³), pooled and randomly assigned to four groups of 10 mice: animals injected with saline solution; animals injected with 1.5 mg kg⁻¹ of daunorubicin (dosage determined as previously reported (Cherbonnier et al, 2002); animals injected with 5 mg kg⁻¹ of daunorubicin and 5 mg kg⁻¹ of rhGH. Daunorubicin was administered as a single intraperitoneal injection on three consecutive days. Recombinant exogenous rhGH was administered subcutaneously as a single injection on four consecutive days, starting 2 days prior to the first injection of daunorubicin. Animal body weights were recorded and tumours were measured with calipers by the same investigator and the volume was calculated according to the following equation: V (mm³) = d₁² (mm²) × D (mm)/2, where d and D are the smallest and perpendicular diameters, respectively. For ethical reasons, the maximum tumour volume accepted was 2000 mm³. In a separate experiment, mice were treated as described above and were killed at various times. Fixed tumours were analysed by epifluorescence for in situ apoptosis with terminal-deoxynucleotidyl-transferase-mediated dUTP nick-end labelling (TUNEL) (Roche) or for NF-κB-regulating apoptosis on tissue sections.

Statistical analysis

Statistical analyses were performed using Student’s t-test for in vitro experiments. In vivo experiments were assessed using a nonparametric Kruskal–Wallis test for tumour volume measurement, using logrank test for Kaplan–Meier curves and a χ² test for the quantification of apoptosis and NF-κB activation on tissue sections.

RESULTS

Human growth hormone increases the sensitivity to TNF-α-induced apoptosis

Based on our previous studies demonstrating that stable expression of hGH in cell lines could mimic the effect of exogenous GH
(Haefner et al., 1999), we exposed our two hGH-producing human myeloid leukaemia U937 cell lines and the control one to TNF-α during 2-day cultures. As illustrated in Figure 1A, the percentage of dead cells (PI +) was higher for U937-hGH cells than for control U937-Neo cells, in response to TNF-α (37.5 ± 9.6% of PI + U937-hGH cells treated with 10 ng ml⁻¹ of TNF-α, vs 16.7 ± 5.6% of PI + cells among TNF-α-treated control cell lines, mean ± s.e.m., P = 0.001, n = 6). In contrast, hGH had no additional effect on apoptosis of cells exposed to TNF-α in the presence of the protein synthesis inhibitor CHX, known to potentiate TNF-α-induced U937 cell death (Cossartizza et al., 1995). The difference between hGH-producing cells and their controls was also demonstrated in terms of apoptotic nuclear events, as evidenced by flow cytometry of permeabilised cells allowing DNA content analysis (Figure 1B). Under these conditions, after 20-h cultures, presence of hGH led also to an increase in hypodiploid DNA in TNF-α-treated cells. Finally, we confirmed that exogenous rhGH added to the cultures of unmanipulated U937 cells rendered them more sensitive to TNF-α-treatment (Figure 1C). Indeed, in these conditions, we observed a statistically significant increased cell death in hGH-treated U937 cells stimulated with 50 ng ml⁻¹ of TNF-α, as compared to U937 cells cultured in the absence of rhGH (44.6 ± 0.7% of dead U937 cells treated with 50 ng ml⁻¹ of TNF-α in the presence of 5 ng ml⁻¹ of rhGH and 51.5 ± 5.5% of dead U937 cells treated with 50 ng ml⁻¹ of TNF-α in the presence of 500 ng ml⁻¹ of rhGH, vs 35.2 ± 0.6% among cells treated with TNF-α in the absence of rhGH, mean ± s.e.m., P < 0.05 and P < 0.01, respectively, n = 4).

Specific depressed NF-κB activation in cells treated with TNF-α by hGH

As inhibition of NF-κB activation was clearly linked to increased apoptosis of various tumour cells, we decided to test NF-κB DNA binding activity in nuclear extracts from our cell lines incubated with TNF-α, a potent NF-κB stimulator (Baeuerle and Baltimore, 1988). As illustrated in Figure 2A, the increase in NF-κB-DNA binding activity observed in U937-Neo cells exposed to TNF-α (lane 2), as compared to nonexposed cells (lane 1), was no longer observed in U937-hGH cells cultured under similar conditions (lanes 4 and 3, respectively). Specificity was assessed by incubating nuclear extracts obtained from TNF-α-treated control cells with nonradiolabelled consensus NF-κB (lane 5) or mutated NF-κB (lane 6) probe. Interactions of these nuclear extracts were also observed with anti-P65 (lane 7) and, to a lesser extent, anti-P50 (lane 8) Abs, confirming the detection of NF-κB.

To confirm the effect of hGH on NF-κB activity, in separate experiment, parental U937 cells were coincubated with TNF-α and various concentrations of rhGH. As shown in Figure 2B, TNF-α-mediated NF-κB-DNA binding activity (lane 4) was decreased by addition of 50 ng ml⁻¹ (lane 6) or 500 ng ml⁻¹ (lane 7) of rhGH.

NF-κB can interact with Fas-mediated apoptosis in various situations (Zong et al., 1998; Dudley et al., 1999; Trauzold et al., 2001; Zheng et al., 2001), which prompted us to investigate the effect of hGH on NF-κB translocation using nuclear extracts from cells exposed to anti-Fas mAb (Figure 2C). No protein–DNA complexes was seen using extracts from U937-Neo and U937-hGH cells exposed to anti-Fas mAb (lanes 4 and 8, respectively). As expected, protein–DNA complexes were observed using nuclear extracts from U937-Neo cells exposed to TNF-α (lane 2), and also to TNF-α + CHX (lane 3), compared to unstimulated cells (lane 1). These protein–DNA complexes were specifically competed by a consensus NF-κB probe but not by the mutated probe (lanes 9 and 10, respectively). The present experiment also confirmed that NF-κB translocation was strongly inhibited by hGH in response to a TNF-α stimulus (lane 6), and was markedly diminished in response to a TNF-α + CHX stimulus (lane 7).

Inhibition of TNF-α induced IκB degradation by hGH

Intracellular localisation of NF-κB can be closely monitored by its interaction with members of the IκB family. In response to various stimuli, IκB undergoes proteolytic degradation, which allows nuclear translocation of NF-κB leading to gene activation (Baeuerle and Baltimore, 1988 #733). To determine whether the decreased activation of NF-κB observed in hGH-treated cells was due to a modulation of IκB degradation, we performed Western blot analyses on whole-cell extracts from our cell lines. After TNF-α exposure, degradation of IκB was observed in U937-Neo cells, while no degradation was detected in U937-hGH cells, even after incubation for 2 h (Figure 3). Interestingly, IκBα (Figure 3) and IκBβ (not shown) were degraded to a similar degree in U937-Neo control and in hGH-producing U937-Neo-cells exposed to TNF-α.
Effects of hGH-induced enhanced GSH production

The activation of NF-κB in response to various agents required the production of reactive oxidative intermediates (ROIs) (Janssen-Heininger et al., 2000). Since glutathione, the most significant intracellular thiol, is a potent ROI scavenger (Meister and Anderson, 1983) with the potential to prevent NF-κB activation, we decided to test whether direct addition of exogenous GSH to U937 could mimic hGH treatment (Janssen-Heininger et al., 2000). We first measured its production in U937-Neo and U937-hGH cells under the conditions described in Materials and Methods. The values represent the mean ± s.e.m. of four independent experiments (*P<0.05). (B) Effect of GSH-OEt on TNF-α-induced apoptosis. U937-Neo cells were stimulated with TNF-α in the presence or absence of GSH-OEt and under the conditions described in Materials and Methods; the percentage of dead cells was measured by PI staining. The values represent the mean ± s.e.m. of three independent experiments (**P<0.01, ***P<0.001). When comparing GSH-OEt treated cells to GSH-OEt non-treated cells in each group, (C) Effect of GSH-OEt on NF-κB activation. Nuclear extracts were analysed by EMSA for measurement of NF-κB activation, as described in Figure 2. (D) Effect of GSH on IκB degradation. Whole-cell extracts were subjected to Western blotting using anti-IκB Abs as described in Figure 3.

**Figure 2.** Effect of hGH on NF-κB activation. (A) An EMSA was performed on nuclear extracts as described in Materials and Methods. Control U937 or hGH-transfected cells were either nonstimulated (lanes 1 and 3, respectively) or stimulated with TNF-α (10 ng ml⁻¹) (lanes 2 and 4, respectively). Nuclear factor-κB migration was assessed by migration of nuclear extracts from U937-Neo cells stimulated with TNF-α, coincubated with nonlabelled NF-κB-specific (lane 5) or NF-κB-mutated probes (lane 6), or with anti-P65 (lane 7) and anti-P50 (lane 8) NF-κB subunit antibodies. (B) In a separate experiment, an EMSA was performed on nuclear extracts from U937-Neo cells cultured in the absence or in the presence of TNF-α (10 ng ml⁻¹) (lanes 5, 6, and 7, respectively). U937-hGH cells were also stimulated with TNF-α (10 ng ml⁻¹) (lane 8). Nuclear factor-κB migration was assessed by migration of nuclear extracts from U937-Neo cells stimulated with TNF-α, and coincubated with nonlabelled NF-κB-specific (lane 2) or NF-κB-mutated probes (lane 1) probes. (C) In another experiment, U937-Neo and U937-hGH cells were either nonstimulated (lanes 1 and 5, respectively), stimulated with TNF-α (10 ng ml⁻¹) (lanes 2 and 6, respectively), stimulated with TNF-α and CHX (400 ng ml⁻¹) (lanes 3 and 7, respectively) or stimulated with anti-Fas mAbs (lanes 4 and 8, respectively). Specificity was assessed by migration of nuclear extracts from U937-Neo cells stimulated with TNF-α, and coincubated with the probes described above, nonlabelled NF-κB-specific (lane 9) or NF-κB-mutated (lane 10) probes.

**Figure 3.** Effect of hGH on IκB degradation. Whole-cell extracts from the indicated cell lines stimulated with TNF-α (10 ng ml⁻¹) for 0–120 min were subjected to Western blotting using anti-IκB Abs under the conditions described in Materials and Methods.
concentration used in this study, and at 20 μM GSH-OEt for both TNF-α concentrations. We then studied the effect of GSH-OEt on both NF-κB activation and IκB degradation. The presence of GSH-OEt depressed NF-κB-DNA binding activity in a dose-dependent manner in U937-Neo cells treated with 10 ng ml⁻¹ of TNF-α (Figure 4C). The presence of GSH-OEt (Figure 4D, lower left) in the culture prevented the degradation of IκB that normally occurred upon TNF-α-treatment only (Figure 4D, upper left). Moreover, addition of DEM, a potent thiol-depleting agent, in cell cultures led to IκB degradation in TNF-α-treated hGH-producing cells (Figure 4D, lower right), while, as expected, a pattern of stabilised IκB was shown in U937-hGH cells with an unmodified thiol level (Figure 4D, upper right). Altogether, these results suggest that hGH may control the response to TNF-α by modifying the redox status of the cells.

**In vivo sensitisation of tumours by rhGH**

To extend and validate this study in vivo, we decided to use the anticancer drug daunorubicin, as TNF-α, one of the main cytokines involved in sepsis (reviewed in Dinarello, 2000), may induce devastating effects after in vivo injection. Moreover, daunorubicin, widely used in clinical practice, is able to induce apoptosis and activate NF-κB in our cells (Cherbonnier et al., 2002). We therefore decided to study the effect of exogenous recombinant hGH on chemotherapy delivered to nude mice engrafted with parental unmodified U937 tumours. In order to verify the proposed mechanism explaining the effect of hGH, in vivo, we first examined in situ apoptosis in the various groups of mice defined in Materials and Methods. A TUNEL assay reported in Figure 5A clearly showed a greater number of fluorescent nuclei, reflecting increased cell death in tumour cells of mice treated with both daunorubicin and rhGH compared to daunorubicin-treated mice (P<0.001), while no fluorescent nuclei were observed in the two other groups. In addition, the limited nuclear staining revealed with an anti-P65 NF-κB subunit Ab, evidenced a marked decrease in NF-κB activation in tumour cells of mice treated with both daunorubicin and rhGH, compared to the daunorubicin-treated group (P<0.0001) (Figure 5B). Both effects were observed 2 days after the last injection of daunorubicin (day 6). Similar analyses performed on days 9 and 12 showed equivalent number of dead cells and lack of NF-κB in cell nuclei, in both daunorubicin-treated groups.

In parallel, the growth rate of U937 tumours was measured in these mice. As shown in Figure 5C, this rate was reduced in mice treated with the highest subtoxic dose of daunorubicin.

**Figure 5** *In vivo* effect of hGH on daunorubicin treatment of engrafted tumours. Small tumour fragments obtained from U937-Neo tumours were transplanted subcutaneously in previously irradiated nude Swiss mice. Tumour-bearing mice either received i.p. injections of saline solution or subcutaneous injections of rhGH alone, or the highest subtoxic dose of daunorubicin (1.5 mg kg⁻¹) with or without 5 mg kg⁻¹ of rhGH. (A) Tissue sections from mice treated as above were submitted to TUNEL assay. Note the significant number of stained nuclei in tumours from rhGH- and daunorubicin-treated animals, indicating a high apoptosis rate in these animals. (B) The same tumours were assessed for NF-κB activation, as evidenced by the presence of the P65 subunit in the nuclei. Note the lower number of stained nuclei in tumours from mice treated with rhGH and daunorubicin, compared with daunorubicin-treated animals. (C) Tumour volumes were measured in each group of mice. The measurement was stopped when a mouse died or was killed because of a tumour volume exceeding 2000 mm³. Each line represents the mean±s.e.m. of the tumour volumes (*P<0.05 and **P<0.01, when comparing daunorubicin-treated mice to mice receiving daunorubicin and rhGH). (D) Kaplan-Meier curve comparing the different groups of mice with a tumour volume below 300 mm³. PBS-injected mice (-----), daunomycin-injected mice (-----), hGH-injected mice (- - -) and daunomycin + hGH-injected mice (---).
(1.5 mg kg$^{-1}$, as defined in Materials and Methods) combined with injections of 5 mg kg$^{-1}$ of rhGH, while tumours remained unaffected by treatment with daunorubicin only. Tumour volumes were significantly different from the 6th day after initiation of treatment until the 12th day, when comparing animals treated with rhGH and daunorubicin to animals treated with daunorubicin only (at day 6: 171 vs 327 ± 53 mm$^3$, n = 10, *P < 0.05 and at day 12: 320 ± 52 mm$^3$ vs 781 ± 159 mm$^3$, n = 10, *P < 0.05). No further comparisons were possible due to death of animals in the daunorubicin-treated group at day 12. No protective effects were observed in mice receiving saline (Ctrl) or rhGH only. Given the high growth rate of U937 cells in vivo and the design of the present experiments in which only a single cure was given to the mice, the complete eradication of tumours could not be achieved. However, the survival of mice with a tumour below 300 mm$^3$ was determined. As shown in Figure 5D, the survival of mice treated with both daunorubicine and rhGH was significantly higher than in the different control groups (*P < 0.008).

It should be noted that coadministration of rhGH and daunorubicin did not induce any toxicity or body weight loss (data not shown).

**DISCUSSION**

In a previous study, we demonstrated the ability of hGH to protect human monocytes or U937 cells from cell death induced by Fas engagement (Haeffner et al, 1999). Interestingly, despite molecular similarities between Fas and TNF-α receptors (Itoh et al, 1991) and common pathways in response to their engagement in various cell lines, including U937 cells (Schütze et al, 1992; Gifone et al, 1993), we report herein that hGH may potentiate TNF-α-induced U937 cell apoptosis (Figure 1). It has been clearly established that the cell death signal mediated via engagement of TNF-α receptor can be regulated by NF-κB activation subunits (Liu et al, 1996); (Van Antwerp et al, 1996; Wang et al, 1996). In our study, we found that NF-κB activation was markedly decreased in U937-hGH cells exposed to TNF-α compared to treated U937-Neo cells (Figure 2A) and in parental cells incubated with exogenous rhGH (Figure 2B). These results therefore confirm our previous findings (Haeffner et al, 1997) concerning the ability of hGH to modulate the NF-κB-dependent pathway in response to various inducers. Fas crosstalk may induce death or survival signalling, depending on the cell type (Budd, 2002). Survival is linked to the engagement of FLICE inhibitory protein (FLIP) that may phosphorylate IκB, thereby activating NF-κB. As anti-Fas mAbs were unable to induce NF-κB activation in our cells (Figure 2C), hGH may trigger another pathway promoting cell survival in response to Fas. This difference in NF-κB profile could therefore partly explain the opposite effects observed with Fas and TNF-α.

As also reported in Figure 1, addition of protein synthesis inhibitor CHX, in control cells cultured with TNF-α, induced an expected increase in cell apoptosis (Cossarizza et al, 1995). Under similar conditions, hGH, although still synthesised, as assessed by ELISA (data not shown) was unable to improve cell death. Moreover, the presence of CHX did not modify the NF-κB profile in either U937-hGH or U937-Neo cells exposed to TNF-α (Figure 2C). We can therefore speculate that hGH and CHX both increase apoptosis by affecting the synthesis of survival proteins: hGH acts upstream to NF-κB activation, while CHX acts downstream to NF-κB activation.

Activation of NF-κB, that is, its translocation in the cell nucleus, occurs after proteosomal degradation of members of the IκB family following phosphorylation by IκB kinases (IKK) (Mercurio and Manning, 1999). One of these kinases, I KKκβ, is essential for the prevention of TNF-α-induced apoptosis (Suntfeleben et al, 2001). The IκB family is composed of several α, β and ε proteins constitutively expressed and present in the cytosol, all sharing the capacity to prevent NF-κB translocation, and the newly described δ protein localised in the nucleus (Yamazaki et al, 2001). Unexpectedly, we report that hGH regulated TNF-α-dependent NF-κB activation via stabilisation of IκBα, and not IκBβ, the main member of the IκB family (Figure 3), or IκBδ (data not shown). Although unusual, this type of situation has already been described by other authors in cells from IκBα-deficient mice in response to TNF-α (Whiteside et al, 1997), or in other models (Doerree and Corley, 1999; Speckner et al, 2000). Fischer et al (1999) also reported that TNF-α may activate NF-κB via degradation of IκBα in human mononcytic THP1 cells. TNF-α-inducing NF-κB activation may therefore involve various members of the IκB family, probably depending on the cell type.

Tumour necrosis factor-α induces the release of ROIs (Goossens et al, 1995) that are also considered to be potent NF-κB activators in many cell types, including tumour cells (Giri et al, 1998; Li and Karin, 1999; Manna et al, 2000). We therefore postulated that hGH may act on apoptosis by downmodulation of ROI production. In order to evaluate this hypothesis, we first assessed the effect of hGH on the level of GSH, the most abundant intracellular thiol and a powerful ROI scavenger. We found that hGH increased GSH production in our tumour cells (Figure 4A). In parallel, we observed that addition of GSH-OEt to unmodified U937 cells exposed to TNF-α led to inhibition of NF-κB activation by IκBα stabilisation (Figure 4C and D), thus mimicking the effect of hGH. Moreover, GSH depletion with 50 μM DEM, a potent thiol-depleting agent, in hGH-producing cells exposed to TNF-α restored the IκB degradation process (Figure 4D). Direct addition of a GSH analog (GSH-OEt) able to enter cells due to its hydrophobic ester groups also increased cell death in TNF-α-treated cell cultures (Figure 4B), thus imitating the ability of hGH to sensitize control U937 cells to TNF-α-induced apoptosis. These last data are in apparent contradiction with several studies, including our own, run in other cell types, showing that GSH may protect cells from a death signal (Deas et al, 1997). However, in line with our findings, a report of experiments in U937 cells clearly revealed that antioxidant reagents may block NF-κB activation and potentiate TNF-α-induced apoptosis (Shrivastava and Aggarwal, 1999). Altogether, our findings clearly suggest that hGH controls NF-κB activation and therefore apoptosis via downmodulation of ROI formation in a cell type-dependent manner when compared to the anticancer drugs used in this study. Thus, depending on the stimulus applied to the cells, hGH may either trigger (Jeay et al, 2000), inhibit (as we have reported in human monocytes exposed to lipopolysaccharides (Haeffner et al, 1997) or decrease (as in the present study) translocation of NF-κB into cell nuclei.

We finally decided to validate our findings in an *in vivo* model. Owing to the high toxicity of TNF-α in *in vivo*, we decided to treat mice with the anticancer drug daunorubicin, one of the most commonly used and broadly active chemotherapeutic agents. Moreover, daunorubicin shares several properties with TNF-α, commonly used and broadly active chemotherapeutic agents. However, daunorubicin is considered to be toxic and broadly active chemotherapeutic agents. Moreover, daunorubicin is considered to be toxic and broadly active chemotherapeutic agents. However, daunorubicin is considered to be toxic and broadly active chemotherapeutic agents.
that more prolonged treatment would extend and improve the efficacy of the therapeutic outcome.

Finally, our model may help to shed some light on one of the various mechanisms controlling NF-κB activation. Following binding to its receptors, hGH induces activation of the Janus kinase 2 (Jak2) (Argentinger et al., 1996), which in turn tyrosine-phosphorylates signal transducers and activators of transcription proteins (STAT) (Ram and Waxman, 1997). These phosphorylated proteins migrate into the nucleus and, by binding to GH-responsive elements, trigger gene transcription. These data must be interpreted in the light of the recently proposed crosstalk between NF-κB and STAT showing either an NF-κB-mediated negative control of STAT phosphorylation (Geymayer and Doppler, 2000), or alternatively, the inhibition of NF-κB mediated by STAT phosphorylation (Luo and Yu-Lee, 2000). It is therefore conceivable that hGH may regulate NF-κB and consequently cell apoptosis via a Jak-STAT-dependent mechanism; this hypothesis is currently being investigated. This should be of interest in the development of new therapeutic modalities designed to improve anticancer chemotherapy.

ACKNOWLEDGEMENTS

We thank Drs Jean-Claude Ameisen (INSERM, Paris, France) and Kenth Gustafsson (ICH, London, UK) for helpful discussions; Gisele Chavanel for her technical assistance throughout this study, Patrice Ardouin (Institut Gustave Roussy, Villejuif) for his kind help in animal studies; Sophie Brenner, Corinne Lecuire and Michael Eppe (students from the Institut Paul Lambin, Brussels, Belgium) for technical help. This work was supported by Association pour la Recherche sur le Cancer and Ligue Nationale contre le Cancer, Comité des Hauts-de-Seine (to FH). CC received a fellowship from Ligue Nationale contre le Cancer, Comité de l’Essonne et du Val de Marne and GC from Targa Therapie.

REFERENCES

Argentinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Cantley LC (1996) Mechanism of signaling by growth hormone receptor. Cell 76: 1089 – 1106

Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, Doppler, 2000), or alternatively, the inhibition of NF-κB mediated by STAT phosphorylation (Luo and Yu-Lee, 2000). It is therefore conceivable that hGH may regulate NF-κB and consequently cell apoptosis via a Jak-STAT-dependent mechanism; this hypothesis is currently being investigated. This should be of interest in the development of new therapeutic modalities designed to improve anticancer chemotherapy.

ACKNOWLEDGEMENTS

We thank Drs Jean-Claude Ameisen (INSERM, Paris, France) and Kenth Gustafsson (ICH, London, UK) for helpful discussions; Gisele Chavanel for her technical assistance throughout this study, Patrice Ardouin (Institut Gustave Roussy, Villejuif) for his kind help in animal studies; Sophie Brenner, Corinne Lecuire and Michael Eppe (students from the Institut Paul Lambin, Brussels, Belgium) for technical help. This work was supported by Association pour la Recherche sur le Cancer and Ligue Nationale contre le Cancer, Comité des Hauts-de-Seine (to FH). CC received a fellowship from Ligue Nationale contre le Cancer, Comité de l’Essonne et du Val de Marne and GC from Targa Therapie.

REFERENCES

Argentinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Cantley LC (1996) Mechanism of signaling by growth hormone receptor. Cell 76: 1089 – 1106

Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, Doppler, 2000), or alternatively, the inhibition of NF-κB mediated by STAT phosphorylation (Luo and Yu-Lee, 2000). It is therefore conceivable that hGH may regulate NF-κB and consequently cell apoptosis via a Jak-STAT-dependent mechanism; this hypothesis is currently being investigated. This should be of interest in the development of new therapeutic modalities designed to improve anticancer chemotherapy.

ACKNOWLEDGEMENTS

We thank Drs Jean-Claude Ameisen (INSERM, Paris, France) and Kenth Gustafsson (ICH, London, UK) for helpful discussions; Gisele Chavanel for her technical assistance throughout this study, Patrice Ardouin (Institut Gustave Roussy, Villejuif) for his kind help in animal studies; Sophie Brenner, Corinne Lecuire and Michael Eppe (students from the Institut Paul Lambin, Brussels, Belgium) for technical help. This work was supported by Association pour la Recherche sur le Cancer and Ligue Nationale contre le Cancer, Comité des Hauts-de-Seine (to FH). CC received a fellowship from Ligue Nationale contre le Cancer, Comité de l’Essonne et du Val de Marne and GC from Targa Therapie.

REFERENCES

Argentinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Cantley LC (1996) Mechanism of signaling by growth hormone receptor. Cell 76: 1089 – 1106

Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, Doppler, 2000), or alternatively, the inhibition of NF-κB mediated by STAT phosphorylation (Luo and Yu-Lee, 2000). It is therefore conceivable that hGH may regulate NF-κB and consequently cell apoptosis via a Jak-STAT-dependent mechanism; this hypothesis is currently being investigated. This should be of interest in the development of new therapeutic modalities designed to improve anticancer chemotherapy.

ACKNOWLEDGEMENTS

We thank Drs Jean-Claude Ameisen (INSERM, Paris, France) and Kenth Gustafsson (ICH, London, UK) for helpful discussions; Gisele Chavanel for her technical assistance throughout this study, Patrice Ardouin (Institut Gustave Roussy, Villejuif) for his kind help in animal studies; Sophie Brenner, Corinne Lecuire and Michael Eppe (students from the Institut Paul Lambin, Brussels, Belgium) for technical help. This work was supported by Association pour la Recherche sur le Cancer and Ligue Nationale contre le Cancer, Comité des Hauts-de-Seine (to FH). CC received a fellowship from Ligue Nationale contre le Cancer, Comité de l’Essonne et du Val de Marne and GC from Targa Therapie.

REFERENCES

Argentinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Cantley LC (1996) Mechanism of signaling by growth hormone receptor. Cell 76: 1089 – 1106

Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, Doppler, 2000), or alternatively, the inhibition of NF-κB mediated by STAT phosphorylation (Luo and Yu-Lee, 2000). It is therefore conceivable that hGH may regulate NF-κB and consequently cell apoptosis via a Jak-STAT-dependent mechanism; this hypothesis is currently being investigated. This should be of interest in the development of new therapeutic modalities designed to improve anticancer chemotherapy.

ACKNOWLEDGEMENTS

We thank Drs Jean-Claude Ameisen (INSERM, Paris, France) and Kenth Gustafsson (ICH, London, UK) for helpful discussions; Gisele Chavanel for her technical assistance throughout this study, Patrice Ardouin (Institut Gustave Roussy, Villejuif) for his kind help in animal studies; Sophie Brenner, Corinne Lecuire and Michael Eppe (students from the Institut Paul Lambin, Brussels, Belgium) for technical help. This work was supported by Association pour la Recherche sur le Cancer and Ligue Nationale contre le Cancer, Comité des Hauts-de-Seine (to FH). CC received a fellowship from Ligue Nationale contre le Cancer, Comité de l’Essonne et du Val de Marne and GC from Targa Therapie.

REFERENCES

Argentinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Cantley LC (1996) Mechanism of signaling by growth hormone receptor. Cell 76: 1089 – 1106

Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, Doppler, 2000), or alternatively, the inhibition of NF-κB mediated by STAT phosphorylation (Luo and Yu-Lee, 2000). It is therefore conceivable that hGH may regulate NF-κB and consequently cell apoptosis via a Jak-STAT-dependent mechanism; this hypothesis is currently being investigated. This should be of interest in the development of new therapeutic modalities designed to improve anticancer chemotherapy.

ACKNOWLEDGEMENTS

We thank Drs Jean-Claude Ameisen (INSERM, Paris, France) and Kenth Gustafsson (ICH, London, UK) for helpful discussions; Gisele Chavanel for her technical assistance throughout this study, Patrice Ardouin (Institut Gustave Roussy, Villejuif) for his kind help in animal studies; Sophie Brenner, Corinne Lecuire and Michael Eppe (students from the Institut Paul Lambin, Brussels, Belgium) for technical help. This work was supported by Association pour la Recherche sur le Cancer and Ligue Nationale contre le Cancer, Comité des Hauts-de-Seine (to FH). CC received a fellowship from Ligue Nationale contre le Cancer, Comité de l’Essonne et du Val de Marne and GC from Targa Therapie.

REFERENCES

Argentinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Cantley LC (1996) Mechanism of signaling by growth hormone receptor. Cell 76: 1089 – 1106

Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, Doppler, 2000), or alternatively, the inhibition of NF-κB mediated by STAT phosphorylation (Luo and Yu-Lee, 2000). It is therefore conceivable that hGH may regulate NF-κB and consequently cell apoptosis via a Jak-STAT-dependent mechanism; this hypothesis is currently being investigated. This should be of interest in the development of new therapeutic modalities designed to improve anticancer chemotherapy.

ACKNOWLEDGEMENTS

We thank Drs Jean-Claude Ameisen (INSERM, Paris, France) and Kenth Gustafsson (ICH, London, UK) for helpful discussions; Gisele Chavanel for her technical assistance throughout this study, Patrice Ardouin (Institut Gustave Roussy, Villejuif) for his kind help in animal studies; Sophie Brenner, Corinne Lecuire and Michael Eppe (students from the Institut Paul Lambin, Brussels, Belgium) for technical help. This work was supported by Association pour la Recherche sur le Cancer and Ligue Nationale contre le Cancer, Comité des Hauts-de-Seine (to FH). CC received a fellowship from Ligue Nationale contre le Cancer, Comité de l’Essonne et du Val de Marne and GC from Targa Therapie.
Lee PD (1996) A randomized, placebo-controlled trial combined insulin-like growth factor 1 and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 81: 2968 – 2975
Li N, Karin M (1999) Is NF-kappaB the sensor of oxidative stress? FASEB J 13: 1137 – 1143
Liu ZG, Hsu H, Goeddel DV, Karin M (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87: 565 – 576
Luo G, Yu-Lee L (2000) Stat5b inhibits NFkappaB-mediated signaling. Mol Endocrinol 14: 114 – 123
Mamma SK, Mukhopadhyay A, Aggarwal BB (2000) Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164: 6509 – 6519
Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52: 711 – 760
Mercurio F, Manning AM (1999) Multiple signals converging on NF-kappaB. Curr Opin Cell Biol 11: 226 – 232
Mollerue B, Deckert M, Deas O, Rieux-Laucat F, Hirsch F, Bernard A, Fischer A, Lynch DH, Charpentier B, Le Diet F, Senik A (1996) CD2-induced apoptosis in activated human peripheral T cells. A Fas-independent pathway that requires early protein tyrosine phosphorylation. J Immunol 156: 3184 – 3190
Myolonas PG, Matsouka PT, Papandionou EV, Vagianos C, Kalfarentzos F, Alexandrides TK (2000) Growth hormone and insulin-like growth factor 1 protect intestinal cells from radiation induced apoptosis. Mol Cell Endocrinol 160: 115 – 122
Oehm A, Behrmann I, Falk W, Pavlita M, Maier G, Klas C, Li-Weber M, Mercurio F, Manning AM (1999) Activators and target genes of Rel/NF-kappaB transcription factor. J Biol Chem 274: 10709 – 10715
Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853 – 6866
Ram PA, Waxman DJ (1997) Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem 272: 17694 – 17702
Saccà L, Fazio S (1996) Cardiac performance: growth hormone enters the race. Nat Med 2: 29 – 31
Schütze S, Potthof K, Machleidt T, Berkovic D, Wiegmann K, Krohne M (1999) NF-kappaB-mediated nuclear factor-kappaB in the nuclei. J Cell Biol 71: 765 – 776
Senthilkumar U, Li ZW, Baud V, Karin M (2001) IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity 14: 217 – 230
Shrivastava A, Aggarwal BB (1999) Antioxidants differentially regulate activation of nuclear factor-kappa B, activator protein-1, c-jun amino-terminal kinases, and apoptosis induced by tumor necrosis factor: evidence that JNK and NF-kappa B activation are not linked to apoptosis. Antioxid Redox Signal 1: 181 – 191
Slomins AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ (2000) A preliminary study of growth hormone therapy for Crohn’s disease. N Engl J Med 342: 1633 – 1637
Spiecker M, Darius H, Liao JK (2000) A functional role of I kappa B-epsilon in endothelial cell activation. J Immunol 164: 3316 – 3322
Tang G, Minemoto Y, Biding B, Purcell NH, Li Z, Karin M, Lin A (2001) Inhibition of IJKB activation through NF-kappaB target genes. Nature 414: 313 – 317
Thieblemont N, Haeffner-Cavaillon N, Haeffner A, Cholley B, Weiss L, Kazatchkine M (1995) Triggering of complement receptors CRI (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappaB (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytes. J Immunol 155: 4861 – 4867
Trauzold A, Wermann H, Artl A, Schütze S, Schaf er H, Oestern S, Roder C, Ungefroren H, Lampe E, Heinrich M, Walczak H, Kalthoff H (2001) CD95 and TRAIL, receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 20: 4258 – 4569
Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM (1996) Suppression of TNF-a-induced apoptosis by NF-kB. Science 274: 787 – 789
Van Buul-Offers SC, Kooijman R (1998) The role of growth hormone and insulin-like growth factors in the immune system. Cell Mol Life Sci 54: 1083 – 1094
van Hooijden M, Rozell BL, Ahrlund-Richter L, Toftrud G (1999) Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59: 3299 – 3303
Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS (1999a) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412 – 417
Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS (1999b) NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19: 5923 – 5929
Wang C-Y, Mayo MW, Baldwin Jr AS (1996) TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science 274: 784 – 786
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680 – 1683
Whiteside ST, Epinat JC, Rice NR, Israel A (1997) I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B superfamily. Sequence identity with the Fas antigen. J Biol Chem 272: 10709 – 10715